Skip to Content

Trodelvy (sacituzumab govitecan) – A new effective treatment option for breast cancer

Data presented at SABCS22 shows that Trodelvy, sacituzumab govitecan, is an effective new treatment option for patients with pre-treated, endocrine-resistant HR+/HER2- metastatic breast cancer.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top